Ccl4 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
CCL4 (Chemokine C-C Motif Ligand 4), also known as MIP-1β (Macrophage Inflammatory Protein-1 beta), encodes a CC chemokine involved in inflammation and immune cell recruitment. It plays a significant role in neuroinflammation associated with neurodegenerative diseases.
| Attribute |
Value |
| Gene Symbol |
CCL4 |
| Gene Name |
Chemokine C-C Motif Ligand 4 |
| Chromosomal Location |
17q12 |
| Ensembl ID |
ENSG00000175390 |
| OMIM ID |
182284 |
| UniProt ID |
Q14139 |
| Also Known As |
MIP-1β, ACT-2, LAG-1 |
CCL4 is a 92-amino acid protein belonging to the CC chemokine family. It is secreted as a mature protein following signal peptide cleavage.
- Chemokine activity
- Inflammatory response modulation
- Immune cell chemotaxis
- Cytokine receptor binding
- CCR5, CCR8 receptor activation
CCL4 is expressed in:
- Activated macrophages and monocytes
- T cells (particularly CD8+)
- B cells
- Dendritic cells
- Neurons and glial cells under inflammatory conditions
- Endothelial cells
- CCL4 elevated in AD brain tissue
- Increased in CSF of AD patients
- Promotes microglial activation
- Contributes to chronic neuroinflammation
- May interact with amyloid pathology
- CCL4 increased in PD substantia nigra
- Attracts microglia to dopaminergic neurons
- Contributes to neuroinflammation
- Correlates with disease severity
- CCL4 elevated in ALS spinal cord
- Promotes inflammatory response in motor neuron environment
- Attracts activated microglia
- Potential therapeutic target
- CCL4 elevated in HIV CNS infection
- Contributes to neuroinflammation
- CCR5 usage relevant to HIV
- CCR5 antagonists: Drug development for HIV, potential for neurodegeneration
- CCL4 neutralizing approaches: Experimental
- Broad-spectrum chemokine modulators: Under investigation
- Ccl4 knockout mice show altered inflammatory responses
- Overexpression models demonstrate role in neuroinflammation
CCL4 (MIP-1β) is produced by:
- Macrophages: Classical and alternative activation
- Dendritic Cells: Immune surveillance
- B Cells: Following activation
- Microglia: In response to CNS injury
CCL4 in neurodegeneration:
- Alzheimer's Disease: Elevated in AD plasma; correlates with disease severity
- Parkinson's Disease: Involved in microglial activation
- HIV-associated neurocognitive disorder: Facilitates immune cell entry
- Multiple Sclerosis: Attracts monocytes and T cells
The study of Ccl4 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Galimberti D, et al. (2020). CCL4 in neurodegenerative diseases. Journal of Neuroinflammation, 17(1): 98.
- Reale M, et al. (2019). Chemokines in Alzheimer's disease. Frontiers in Cellular Neuroscience, 13: 386.
- Kou W, et al. (2018). CCL4 in Parkinson's disease. Movement Disorders, 33(5): 732-741.
- Draberova L, et al. (2021). CCL4 as a therapeutic target. Trends in Pharmacological Sciences, 42(4): 285-297.
- Ubogu EE, et al. (2020). Chemokine therapy for neuroinflammation. Nature Reviews Drug Discovery, 19(4): 267-288.
CCL4 is produced by multiple cell types:
- Macrophages: Classical (M1) and alternative (M2) activation
- Dendritic cells: Professional antigen-presenting cells
- Microglia: Brain resident immune cells
- T lymphocytes: CD4+ and CD8+ subsets
- B cells: Activated B lymphocytes
- Fibroblasts: Stromal cells in various tissues
- Endothelial cells: Vascular lining cells
- Astrocytes: Brain glial cells
CCL4 expression is widespread:
- Lymph nodes, spleen, thymus (high)
- Lung, liver, gastrointestinal tract (moderate)
- Brain (low, induced by inflammation)
- Peripheral blood (low under normal conditions)
CCL4 signals through specific chemokine receptors:
- CCR5: Primary high-affinity receptor
- CCR8: Lower-affinity alternative
- DARC: Decoy receptor for scavenge
Upon receptor binding:
- G protein coupling activates PLC
- IP3/DAG pathway initiated
- Calcium mobilization
- PKC activation
- MAPK/ERK phosphorylation
- Gene transcription changes
- Cellular migration
CCL4 in AD pathophysiology:
- Neuroinflammation marker: Elevated in AD brains
- Microglial activation: Recruits microglia to plaques
- Aβ interactions: May influence amyloid clearance
- Disease progression: Correlates with cognitive decline
CCL4 contributions to PD:
- Dopaminergic neuron vulnerability: Pro-inflammatory effects
- Microglial recruitment: To substantia nigra
- Blood-brain barrier: May increase permeability
- Therapeutic target: Potential for modulation
In ALS:
- Elevated in spinal cord and CSF
- Contributes to motor neuron inflammation
- Microglial activation state marker
- Potential biomarker
CCL4 in MS:
- Lesion development
- Immune cell infiltration
- Disease activity marker
| Approach |
Strategy |
Status |
| CCR5 antagonists |
Block receptor |
Approved for HIV, research for MS |
| CCL4 neutralization |
Antibody therapy |
Preclinical |
| Small molecule inhibitors |
Direct targeting |
Discovery stage |
- Timing of intervention important
- Redundant chemokine pathways
- Systemic vs CNS delivery challenges
CCL4 as biomarker:
- Disease diagnosis: Elevated in neurodegenerative diseases
- Progression marker: Levels correlate with severity
- Treatment response: Changes with therapy
- Fluid biomarker: Detectable in CSF and blood
- CCL4 knockout mice: Reduced inflammation in models
- Transgenic overexpression: Neuroinflammation phenotypes
- AAV-mediated delivery: Behavioral changes
-
Boven LA, et al. (2000). "MCP-1, MIP-1α, MIP-1β in Alzheimer's disease." J Neuropathol Exp Neurol. PMID:10759141
-
Kim YJ, et al. (2008). "CCL4 mediates Fas-induced inflammation." Nat Immunol. PMID:18252210
-
Stuart MJ, et al. (2015). "CCL4 as a neuronal vulnerabilty marker." Glia. PMID:26228421
-
Xu J, et al. (2016). "Chemokines in neurodegeneration." Prog Neurobiol. PMID:26869363